Abstract
The ongoing responses to the COVID-19 pandemic have resulted in diverse vaccine-based solutions that are advancing our understanding of medical science.1 Randomised, placebo-controlled clinical trials are providing a unique opportunity to compare the safety and immunogenicity of several different vaccine platforms, including vectored, DNA, inactivated virus, mRNA, and protein subunit vaccines. Strategic differences within each vaccine platform, such as dimer versus trimer protein subunits or modifications in protein design based on dynamic structural modelling, are providing deeper insights into the optimal vaccines of the future—a silver lining to the dark cloud of the COVID-19 pandemic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
